U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.36
    -0.43 (-1.90%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.16%)
     
  • BTC-USD

    48,595.92
    +747.33 (+1.56%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Sense Doubles Footprint with New Research and Development Facility

·1 min read

With expected approval and first product launch near, research team moves into new facility

BOSTON & OXFORD, England, September 14, 2021--(BUSINESS WIRE)--Global molecular diagnostics innovator, Sense Biodetection (Sense) today announced the relocation of its expanded Research and Development (R&D) function to The Quadrant at Abingdon Science Park, one of the leading locations in Oxfordshire for science innovation.

The move doubles Sense’s existing laboratory capacity, enhancing the firm’s capability to accelerate the development of a broad test menu on its Veros™ molecular platform. As part of Sense’s global innovation and expansion strategy, the new R&D facility features modern office spaces and large suites of molecular discovery and development laboratories.

"This expansion complements our global strategy to launch a portfolio of highly accurate, point-of-care tests for a range of diseases - stretching far beyond the forthcoming launch of the Veros™ COVID-19 test," said Sense Founder and Chief Business Development Officer, Harry Lamble, Ph.D. "This is a significant step for our future, increasing space to accommodate our growing and talented team of scientific innovators to deliver rapid, accurate, point-of-care testing solutions."

About Sense

Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results though easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, and Earlybird Health, Sense is growing rapidly as it prepares to launch Veros COVID-19 and build a portfolio of tests for other diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005317/en/

Contacts

Jenna Kane
jennad@healthandcommerce.com
480.388.9587